// App-Quantinova.ai

: Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study

Researchers

Presenter

  • Andrew M. Evens

Principal Investigators

  • Anas Younes

  • Stephen M. Ansell

  • Won Seog Kim

  • John Radford

  • Tatyana A. Feldman

  • Joseph Tuscano

  • Kerry J Savage

  • Yasuhiro Oki

  • Andrew P. Grigg

  • Christopher Pocock

  • Monika Dlugosz-Danecka

  • Keenan Fenton

  • Gerald Engley

  • Rachael Liu

  • Harry Miao

  • Hina Jolin

  • Ashish Gautam

  • Andrea Gallamini

Medical Centers

  • Division of Blood Disorders,Rutgers Cancer Institute of New Jersey,New Brunswick, NJ,United States

  • BC Cancer Centre for Lymphoid Cancer,Vancouver,Canadá

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Mayo Clinic, Rochester, MN

  • Samsung Medical Center, seoul, CA, Korea, Republic of (South)

  • Manchester Academic Health Science Centre, University of Manchester, Manchester University NHS Foundation Trust, Manchester, United Kingdom.

  • John Theurer Cancer Centre, Hackensack University Medical Center, Hackensack, NJ

  • UC Davis Cancer Center, Sacramento, CA

  • British Columbia Cancer Agency Center for Lymphoid Cancer, Vancouver, BC, Canada

  • 1.MD Anderson Cancer Center, Houston, TX

  • Olivia Newton-John Cancer Wellness and Research Centre, Austin Health and Department of Clinical Haematology, Austin Hospital, Heidelberg, VIC, Australia

  • Kent & Canterbury Hospital, Kent, United Kingdom

  • Department of Hematology, Jagiellonian University Hospital, Krakow, Poland

  • Seattle Genetics, Bothell, WA

  • Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Deerfield, IL

  • Research Innovation and Statistics, Antoine-Lacassagne Cancer Centre, Nice, France

Locations

  • United States

  • Canada

  • Republic of South Korea

  • United Kingdom

  • Australia

  • Poland

  • France

Companies

  • Seattle Genetics, In

  • Millennium Pharmaceu

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hodgkin's Lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT01476410

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved